Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
Hepatocellular carcinoma (HCC) is a type of liver cancer. In this study, doctors want to see if a special radiation therapy called adjuvant simultaneously integrated boost (SIB) radiotherapy helps patients who had a liver surgery called hepatectomy with a small margin (less than 1 cm) around the tumor. The study uses two kinds of radiation methods: IMRT (Intensity-Modulated Radiation Therapy) and VMAT (Volumetric Modulated Arc Therapy). These methods help aim radiation precisely at the cancer area while protecting nearby healthy tissues. The study will last for 3 years, and they want to see how many patients live without cancer returning. Patients in the study will receive radiation 23-25 times. Doctors are checking for side effects and how well the treatment works.
- Participation involves 23-25 radiation sessions.
- The study checks patient’s health over 3 years.
- Participants must be adults with no other major illnesses.
Study details
NCT06205472
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
24 January 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.